<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Additional sex combs like 1 (Asxl1) gene is 1 of 3 mammalian homologs of the Additional sex combs (Asx) gene of Drosophila </plain></SENT>
<SENT sid="1" pm="."><plain>Asx is unusual because it is required to maintain both activation and silencing of <z:chebi fb="0" ids="46904">Hox</z:chebi> genes in flies and mice </plain></SENT>
<SENT sid="2" pm="."><plain>Asxl proteins are characterized by an amino terminal homology domain, by interaction domains for nuclear receptors, and by a C-terminal plant homeodomain protein-protein interaction domain </plain></SENT>
<SENT sid="3" pm="."><plain>A recent study of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) revealed a high incidence of truncation mutations that would delete the PHD domain of ASXL1 </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we show that Asxl1 is expressed in <z:hpo ids='HP_0000001'>all</z:hpo> hematopoietic cell fractions analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>Asxl1 knockout mice exhibit defects in frequency of differentiation of lymphoid and myeloid progenitors, but not in multipotent progenitors </plain></SENT>
<SENT sid="6" pm="."><plain>We do not detect effects on hematopoietic stem cells, or in peripheral blood </plain></SENT>
<SENT sid="7" pm="."><plain>Notably, we do not detect severe myelodysplastic phenotypes or <z:hpo ids='HP_0001909'>leukemia</z:hpo> in this loss-of-function model </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that Asxl1 is needed for <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis </plain></SENT>
<SENT sid="9" pm="."><plain>The mild phenotypes observed may be because other Asxl genes have redundant function with Asxl1, or alternatively, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or oncogenic phenotypes may result from gain-of-function Asxl mutations caused by genomic amplification, gene fusion, or truncation of Asxl1 </plain></SENT>
</text></document>